Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax

Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2, is currently in phase I clinical trials for multiple myeloma. Results suggest that venetoclax is only active in a small cohort of patients therefore we wanted to determine its efficacy when used in combination. Combining...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leukemia
Autori principali: Matulis, Shannon M., Gupta, Vikas A., Nooka, Ajay K., Von Hollen, Hayley, Kaufman, Jonathan L., Lonial, Sagar, Boise, Lawrence H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874660/
https://ncbi.nlm.nih.gov/pubmed/26707935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.350
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi